---
title: "CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294820447.md"
description: "CEL-SCI published peer-reviewed results from its IT-MATTERS trial in Oral Oncology, indicating that oral cancer patients with low/zero PD-L1 expression and no lymph node involvement derive significant survival benefits from Multikine treatment prior to surgery. These findings support a differentiated positioning against checkpoint inhibitors. Consequently, CEL-SCI is preparing enrollment for a global confirmatory registration study involving 212 patients within this specific biomarker-defined population to validate the observed survival advantage."
datetime: "2026-08-04T12:02:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294820447.md)
  - [en](https://longbridge.com/en/news/294820447.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294820447.md)
generator: "portal-rs"
---

# CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefit

-   CEL-SCI published peer-reviewed results in Oral Oncology from its IT-MATTERS trial; results were already presented in the journal publication. \* Study supports using low or zero PD-L1 expression and no lymph node involvement to identify oral cancer patients most likely to benefit from Multikine. \* Biomarker-selected patients treated with Multikine before surgery showed better survival outcomes than standard care alone, supporting a differentiated positioning versus checkpoint inhibitors. \* Enrollment is being prepared for a 212-patient global confirmatory registration study in the same biomarker-defined population to validate the earlier survival benefit. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040800BIZWIRE\_USPR\_\_\_\_\_20260804\_BW733241) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CVM.US](https://longbridge.com/en/quote/CVM.US.md)

## Related News & Research

- [Corcept names Roberto Vieira as President, Oncology in initial beneficial ownership filing](https://longbridge.com/en/news/297971867.md)
- [CNS Pharma targets oncology, neurology in-licensing to build new therapy pipeline](https://longbridge.com/en/news/297657028.md)
- [10:30 ETBiosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/297801421.md)
- [Corcept Oncology President Roberto Wandenkolk Vieira disposes of USD 6.31 million in common shares](https://longbridge.com/en/news/297973214.md)
- [Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer | CAI Stock News](https://longbridge.com/en/news/297788849.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**